Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 3 years in the treatment of knee osteoarthritis. A prospective multicentre, international, double-blind, placebo-controlled study

Next Previous
Trial Profile

The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 3 years in the treatment of knee osteoarthritis. A prospective multicentre, international, double-blind, placebo-controlled study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Strontium ranelate (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms POLKA; SEKOIA
  • Sponsors Servier

    • Most Recent Events

    • 22 Aug 2020 Results assessing the utility of two alternative statistical modelling methods for monitoring KOA progression presented at the 2020 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 22 Apr 2018 Results (n=1206) assessing data from follow-up study planned over 5-year, conducted in patients with a primary knee osteoarthritis having participated in the previous CL3-12911-018 study, were presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 05 Apr 2014 Results of an analysis of the placebo arm presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top